Sofinnova Ventures — 2017 Investments

2 investments dated 2017 · listed companies and verified rows first · show all

Apellis Pharmaceuticalsapellis.com in 𝕏Aug 2017acquired by Biogen · May 2026 · $5.6B

NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.

BiotechCrestwood, US

Pascal Deschatelets(Executive Officer)inCedric Francois(Executive Officer, Director)in

BoardGerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)A. Sinclair Dunlop(Director)

Board seatMaha Katabi· per SEC Form D

Co-investorsAvoro Capital Advisors EMBL Ventures Epidarex Capital F-Prime Capital Keyhorse Capital Solasta Ventures +1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Entellus Medical

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.